Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-09-22
2010-10-05
Epps-Smith, Janet (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S325000, C435S375000, C435S455000
Reexamination Certificate
active
07807647
ABSTRACT:
The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers.
REFERENCES:
patent: 5286717 (1994-02-01), Cohen et al.
patent: 5705188 (1998-01-01), Junichi et al.
patent: 5840497 (1998-11-01), Holliday
patent: 5874416 (1999-02-01), Sheikhnejad
patent: 6177274 (2001-01-01), Park et al.
patent: 6287591 (2001-09-01), Semple et al.
patent: 6440743 (2002-08-01), Kabanov et al.
patent: 7022831 (2006-04-01), Reed
patent: 2004/0006036 (2004-01-01), Hu et al.
patent: 2004/0241651 (2004-12-01), Olek et al.
patent: 2005/0176025 (2005-08-01), McSwiggen et al.
patent: 2005/0181037 (2005-08-01), Ahmad et al.
patent: 2005/0203042 (2005-09-01), Frieden et al.
patent: WO 94/17086 (1994-08-01), None
patent: WO 96/18732 (1996-06-01), None
patent: WO 0177384 (2001-10-01), None
patent: WO 2004/050885 (2004-06-01), None
Jen et al. Stem Cells, vol. 18, 2000, pp. 307-319.
Opalinska et al. Nature Reviews Drug Discovery, 2002, vol. 1, pp. 503-514.
Bocchetta et al. 2004, Oncogene, vol. 23, pp. 6484-6491.
Morris et al. Clinical Cancer Research, 2002, vol. 8, pp. 679-683.
Chirila et al. Biomaterials, vol. 23, 2002, pp. 321-342.
Christman, Judith K., et al., “5- Methyl-2'-deoxycytidine in single-stranded DNA can act in cis to signaldenovo DNA methylation”,Proc. Natl. Acad. Sci. USA, vol. 92, pp. 7347-7351 [1995].
Heckman, Caroline A., et al., “A-Myb Up-regulates Bcl-2 through a Cdx Binding Site in t(14;18) Lymphoma Cells”,The Journal of Biological Chemistry, vol. 275, No. 9, pp. 6499-6508 [2000].
Mohammad, Ramzi, et al., “Bcl-2 Antisense Oligonucleotides are Effective against Systemic but not Central Nervous System Disease in Severe Combined Immunodeficient Mice Bearing Human t(14;18) Follicular Lymphoma”,Clinical Cancer Research, vol. 8, pp. 1277-1283 [2002].
Olivas, Wendy M. and Maher, L. James, III, “Binding of DNA oligonucleotides to sequences in the promoter of the humanbcl-2gene”,Nucleic Acids Research, vol. 24, No. 9, pp. 1758-1764 [1996].
Shen, Changxian, et al., “Targetingbcl-2by Triplex-Forming Oligonucleotide—A Promising Carrier for Gene—Radiotherapy,”Cancer Biotherapy&Radiopharmaceuticals, vol. 18, No. 1, pp. 17-26 [2003].
Shen, Changxian, et al., “Triplex forming oligonucleotide targeted to 3'UTR downregulates the expression of thebcl-2proto-oncogene in HeLa cells”,Nucleic Acids Research, vol. 29, No. 3, pp. 622-628 [2001].
Tufarelli, Cristina, et al. “Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease”,Nature Genetics, vol. 34, No. 2, pp. 157-165 [2003].
Goodwin Neal
Olson David
Sheikhnejad Gholamreza
Epps-Smith Janet
Honigman Miller Schwartz and Cohn LLP
Murphy Kelly T.
O'Brien Jonathan P.
ProNAI Therapeutics, Inc.
LandOfFree
Methods and compositions for cancer therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for cancer therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for cancer therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4177921